Corporate & Investor Presentation
Why invest? - driving long-term shareholder value
Market Dynamics
Growth & Innovation
Financial Results
• Underpenetrated markets in
sleep and COPD
• Healthcare costs continue to
increase
• Focus on improving patient
outcomes
• Value-based technology
solutions
• Global leader in digital health
for sleep and respiratory care
• Long-term growth
opportunities
•6,000+ patents and designs
•~7-8% of revenue invested in
R&D
• Historical revenue and profit
growth
.
• Recurring revenue
• Operating excellence program
• Strong track record of
disciplined capital deployment
Total Shareholder Return (NYSE shares as of 6/30/2020):
1-yr 59%
3-yr 157%
☐
5-yr 270%
5 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20
ResMedView entire presentation